<DOC>
	<DOCNO>NCT01485952</DOCNO>
	<brief_summary>The primary objective study provide biological sample patient Huntington 's disease allow characterisation pharmacological mechanism action SEN0014196 .</brief_summary>
	<brief_title>An Exploratory Clinical Trial Early Stage Huntington 's Disease Patients With SEN0014196</brief_title>
	<detailed_description>This study establish acute phenotypical biological effect repeat dose application SEN0014196 patient Huntington 's disease , provide biomaterials biomarker study ( level circulate huntingtin , acetylation status mutant huntingtin , innate immune marker , transcriptional profile ) . Evaluation phenotypic effect include UHDRS score , total functional capacity . Safety assessment include ECG , vital sign , laboratory safety test physical examination .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Patients early Huntington 's Disease ( age : 18 70 year ) , i.e . genetically confirm ( CAG repeat length ≥36 ) HD , motor sign HD ( motor score UHDRS &gt; 5 ) TFC ≥7 . All patient body weight great 50 kg . Female subject must surgically sterile postmenopausal , spontaneous menstruation least one year first dose , nonlactating negative urine pregnancy test . Male subject participate trial female contraception time take first dose study drug three month take last dose . This must include condom barrier method . All subject must capable provide write informed consent . Subjects must clinically significant relevant history could affect conduct study evaluation data , ascertain Investigator detail medical history screen assessment . Participation study investigational drug within 30 day baseline visit . Subjects presence psychosis and/or confusional state . Subjects clinically significant laboratory ECG abnormalities Screening . Subjects clinically relevant hematological , hepatic , cardiac renal disease . A medical history infection human immunodeficiency virus , hepatitis C and/or hepatitis B . Any relevant condition , behaviour , laboratory value concomitant medication , opinion Investigator , make subject unsuitable entry study . Subjects previously receive histone deacetylase inhibitor e.g . vorinostat participate clinical trial use compound suspect interfere protein acetylation status . A history malignancy type within 2 year prior screen . A history surgically excise nonmelanoma skin cancer permit . Subjects significant history drug allergy determine Investigator . Subjects significant history alcoholism drug/chemical abuse determine Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Huntington Disease</keyword>
	<keyword>Basal Ganglia Diseases</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Dementia</keyword>
	<keyword>Chorea</keyword>
	<keyword>Dyskinesias</keyword>
	<keyword>Movement Disorders</keyword>
	<keyword>Heredodegenerative Disorders , Nervous System</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Cognition Disorders</keyword>
	<keyword>Mental Disorders</keyword>
</DOC>